|1.||Matsumoto, Masayasu: 4 articles (07/2014 - 09/2005)|
|2.||Uchiyama, Shinichiro: 4 articles (07/2013 - 09/2003)|
|3.||Bennett, Charles L: 4 articles (06/2013 - 02/2009)|
|4.||Raife, Thomas J: 4 articles (06/2013 - 01/2004)|
|5.||Shinohara, Yukito: 4 articles (05/2012 - 04/2003)|
|6.||Winters, Jeffrey L: 3 articles (06/2013 - 02/2009)|
|7.||Ortel, Thomas L: 3 articles (06/2013 - 02/2009)|
|8.||Kwaan, Hau C: 3 articles (06/2013 - 02/2009)|
|9.||McKoy, June M: 3 articles (06/2013 - 02/2009)|
|10.||Zheng, X Long: 3 articles (06/2013 - 02/2009)|
03/01/1996 - "Thus, ticlopidine is effective in reducing the risk of recurrent cerebral ischaemia and stroke. "
10/01/1993 - "Ticlopidine may also be effective in reducing the risk of recurrent stroke in patients who have had a completed thromboembolic stroke."
10/01/1993 - "Two large, multicenter trials have shown that ticlopidine is effective in reducing the risk of fatal and nonfatal stroke in both men and women. "
06/01/1992 - "Ticlopidine is effective for both primary and secondary stroke prevention. "
01/01/2009 - "Few studies examined the role of ticlopidin in acute stroke setting the results showed treatment with ticlopidine improved the neurologic outcome. "
03/01/1993 - "Since shear-induced platelet aggregation can cause thrombotic occlusions in stenotic arterial vessels, our findings may explain the therapeutic efficacy of ticlopidine in arterial thrombosis."
01/01/1983 - "Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications."
01/01/2006 - "In j-Cypher trial, a observational registry trial in Japan, revealed that the subacute thrombosis rate was lower level of the other studies and safety of DES utilization with ticlopidine based antiplatelet regimen. "
07/01/2010 - "By multivariate analysis, HHD (p<0.01), ticlopidine (p=0.01), and CRP (p=0.03) were independently associated with LA thrombus. "
05/01/2007 - "These late thromboses occurred about 2 years after SES implantation and over 1.5 years after discontinuation of ticlopidine."
01/01/2012 - "This trial compared ticlopidine to placebo and did not demonstrate any statistically significant differences for all-cause mortality, vascular mortality or myocardial infarction. "
04/01/2003 - "A 52-year-old man with acute myocardial infarction developed respiratory distress 2 days after receiving ticlopidine for coronary artery stenting. "
10/01/1999 - "A 54-year-old man had been treated with Ticlopidine for antithrombotic therapy after a myocardial infarction. "
11/01/1998 - "The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions."
12/01/1991 - "Nevertheless, this report strongly suggests that such patients can benefit from antiplatelet treatment with ticlopidine; the benefit mainly depends on the protective effect against myocardial infarction."
05/01/2002 - "Gastrointestinal side effects, including bleeding, have been reported with use of ticlopidine in most of the vascular prevention trials. "
04/01/2012 - "The system organ classes with significant disproportionality for ticlopidine included White Cell Disorders (ROR=22.43, 95% CI 18.54-27.12), Red Cell Disorders (8.22; 6.03-11.18), Liver And Biliary System (6.67; 5.35-8.32), Platelet, Bleeding & Clotting (6.59; 5.16-8.40). "
11/01/1998 - "Nevertheless, hemorrhage continues to be a problem with ticlopidine therapy."
09/01/1994 - "Ticlopidine, bleeding, and surgery."
11/01/1993 - "Ticlopidine was tolerated better and no bleeding complications were recorded. "
06/01/1997 - "Despite the potential benefits of therapy with ticlopidine observed in these studies, hematologic monitoring is required to detect neutropenia that may occur during ticlopidine therapy. "
01/01/2009 - "Authors describe a case of neutropenia induced by ticlopidine. "
01/01/2009 - "[Neutropenia induced by ticlopidine: a delayed onset case]."
07/01/2002 - "[Severe neutropenia induced by ticlopidine. "
07/01/2001 - "The patient evolved with neutropenia induced by ticlopidine after 10 days of treatment. "
|1.||Aspirin (Acetylsalicylic Acid)
|4.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|2.||Angioplasty (Angioplasty, Transluminal)
|4.||Renal Dialysis (Hemodialysis)